NCT02542605View on ClinicalTrials.gov

To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

November 11, 2015

Primary Completion Date

September 28, 2017

Study Completion Date

November 8, 2017

Conditions
Migraine
Interventions
DRUG

Erenumab

Administered once on day 1 of Part B of the study by intravenous infusion.

DRUG

Placebo

Administered once on day 1 of Part B of the study by intravenous infusion.

DRUG

PACAP-38 Challenge Agent

"Administered by intravenous infusion during Part A of the study for dose selection for Part B.~Administered by intravenous infusion on day 8 in Part B as a challenge agent to induce a migraine-like attack."

Trial Locations (3)

3000

Research Site, Leuven

92801

Research Site, Anaheim

2333 CL

Research Site, Leiden

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT02542605 - To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients | Biotech Hunter | Biotech Hunter